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Mitochondrial DNA quantification by qPCR is used in the context of many diseases and toxicity 
studies but comparison of results between laboratories is challenging.  Through two multigroup 
distributions of DNA samples from human cell lines, the MITONAUTS group anonymously compared 
mtDNA/nDNA quantification across nine laboratories nvolved in HIV research worldwide.  Eight of 
the nine sites showed significant correlation betwen them (mean raw data R2=0.664; log10-
transformed data R2=0.844).  Although mtDNA/nDNA values were well correlated between sites, the 
inter-site variability on the absolute measurements remained high with a mean (range) coefficient of 
variation of 71 (37-212) %.  Some variability appeared cell line-specific, probably due to chromosomal 
alterations or pseudogenes affecting the quantification of certain genes, while within cell line 
variability was likely due to differences in calibration of the standard curves.  The use of two mtDNA 
and two single copy nDNA genes with highly specific primers to quantify each genome would help 
address copy number variants.  Our results indicate th t sample shipment must be done frozen and that 
absolute mtDNA/nDNA ratio values cannot readily be compared between laboratories, especially if 
assessing cultured cell mtDNA content.  However, within laboratory and relative mtDNA/nDNA 
comparisons between laboratories should be reliable.  
 
 



















Mammalian mitochondria contain their own genome, a circular 16.5 kb mitochondrial DNA 
(mtDNA) that encodes genes for 13 polypeptides, 22 tRNA, and 2 rRNA.  Mitochondrial DNA is 
replicated by human polymerase γ, and the amount of mtDNA per cell can vary according to 
biogenesis and retrograde regulation.  This regulation is affected by cell type and cellular energy 
demands, but can also be influenced by mitochondrial isease or dysfunction, acquired drug-related 
mitochondrial toxicity (Gerschenson and Brinkman 2004), and oxidative stress from various sources 
such as aging, cancer, and smoking (Cote 2005; Masayesv , Mambo et al. 2006; Higuchi 2007; 
Copeland 2008).  Quantification of the relative ratio between mtDNA and nuclear DNA, the latter 
usually assumed to remain constant in human tissue, i  therefore relevant to the study of many diseases 
and conditions, using either clinical, animal or cultured cell derived samples.   
In 2005, representatives from 18 research groups around the world mostly involved in HIV 
drug toxicity research met for the first technical meeting of mtDNA researchers in Boston.  During the 
meeting, methodologies were shared and the usefulness and standardization of mtDNA quantification 
between laboratories were discussed.  Later that year, during a second meeting of the same group in 
Dublin, it was agreed that mtDNA quantity should be expressed as mtDNA/nDNA ratio as opposed to 
mtDNA copies per cell as few assays actually count cells but rather assume 2 copies of nDNA per cell, 
which is not true for all human tissues.  The term MITONAUTS, standing for MITOchondria Network 
for Assay Utilization and Technique Standardization was coined and the present study designed, to 
compare mtDNA quantification between laboratories.  The goal of this study was to assess the 
concordance between laboratories that quantify mtDNA using varied quantitative PCR assays and to 















2. Materials and methods 
For ethical and international shipping regulation issues, we elected to use DNA extracted from 
human cell lines as opposed to human clinical samples.  This presented definite advantages but also 
raised some comparison issues as discussed later.  
 
2.1 DNA preparation 
Table 1 summarizes the source of the human DNA samples. For the first shipment, total DNA 
was extracted from cultured human cells (see Table 1, l ft column) using QiaAmp DNA midi kit 
(Qiagen, Hilden, Germany). The DNA was resuspended in Tris-EDTA buffer and aliquoted (50 µL per 
tube).  For sample #9, a larger volume (200 µL) of DNA was provided, to be used as internal contr l in 
future experiments.  The first shipment samples’ DNA concentration ranged from 57 to 150 ng/µL.   
For the second shipment, DNA was also extracted from cultured human cells (see Table 1, right 
column) using the QiaAmp DNA mini kit (QIAGEN) and resuspended in Tris-EDTA buffer.  The 
samples’DNA concentration ranged from 11 to 67 ng/µL.   
In several instances, samples were prepared by treating a single cell line with drugs that 
modulate mtDNA content.  For example, in the first shipment, four samples were derived from CEM 
cells exposed to nucleoside reverse transcriptase inhibitors (NRTI) for 7 days (Galluzzi, Pinti et al. 
2005) while in the second shipment, 11 of the 20 samples were DNA extracted from K562 cells 
exposed to the NRTI zidovudine or stavudine (Papp, Gadawski et al. 2008).   
 
2.2 Shipping 
For the first shipment, two identical sets of 19 DNA samples were shipped by courier (DHL) to 
each participating laboratory from Modena, Italy, at room temperature.  Each site was asked to ship 
one set back to the sender, also at room temperatur to evaluate if shipping added to variability.  For 
the second shipment, a single set of 20 DNA samples was shipped on dry ice from Vancouver, Canada, 
by FEDEX. 
  
2.3 MtDNA quantification assays 
Each site used its own mtDNA quantification assay methodology and reagents.  Details on the 
methods used are presented in Table 2, in alphabetic l order (unrelated to the order of the other result 















gene typically used to quantify mtDNA depletion in human clinical samples yielded different results in 
cell line-derived samples.  It was agreed that the data would remain anonymous. For this study, the fre
software Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to blast the 
human genome with each set of primer against its intended target, under 55ºC to 63ºC PCR conditions.  
The size of the amplified fragment and the likelihood of amplifying unintended targets with each 
primer pair, based on the Primer-BLAST results, are reported in Table 2. 
 
2.4 Statistical considerations 
For statistical analyses, mtDNA/nDNA values were compared using Pearson’s correlations 
(XLstat 2009). For correlations, data from all site were included.  However, when analyzing 
variability between sites, data from site #2 were omitted since that site reported relative mtDNA/nDNA 
content and not the absolute ratio as for the other sit s.  Statistical analyses were performed on both



















3.1 First shipment at room temperature 
3.1.1 Sample mtDNA/nDNA stability 
Globally, eighteen laboratories initially participated in this exercise and were sent two sets of 
19 DNA samples extracted from 12 distinct human derived cell lines (Table 1) from Modena, at room 
temperature.  Of those 18 sites, 11 shipped back one set of samples that were stored frozen until all 
shipments were received.  The mtDNA content of each returned sample was then assayed by the 
Modena laboratory and compared (Pearson’s correlation) with the values obtained for the set that never 
left Modena.  As seen in Table 3, ten of the eleven returned sets of samples gave values that were 
generally higher than those of the reference set, with the traveling set showing an average change in 
mtDNA/nDNA ratio of +88% compared to the non-traveling set.  Of note, the two sets of sample 
showing the lowest correlations between the reference mtDNA/nDNA ratio measured by Modena and 
the returned set of samples (Table 3) also happened to be those that traveled the longest distance.   
 
3.1.2 MtDNA/nDNA concordance between sites 
Eight sites submitted mtDNA/nDNA ratio data for the 19 samples.  Data from one site (#2) were 
expressed as relative rather than absolute mtDNA/nDNA ratios with values approximately 300 times 
lower than all others.  For that reason these data were only included in correlation analyses.  Using 
both raw and log10-transformed data, results from each site were correlated to those of the other 8 sites 
individually (Table 4A).  In this one on one comparison between each of the participating sites, five 
sites showed good correlations between them (#1, 3, 6, 8 and 9, all p<0.0001) while site #7 showed 
weaker correlation with those same five sites (raw d ta R2≥0.272, p≤0.022; log10 R
2=0.250, p≤0.029).  
Three sites (#2, 4 and 5) showed poor correlation with the other sites with the exception that site 2 
showed a strong correlation with site 4 (raw data R2=0.485, p=0.001; log10 R
2=0.479, p=0.001) and a 
weak one with site 7 (raw data R2=0.266, p=0.024; log10 R
2=0.204, p=0.052).  This discordance was 
greatly ameliorated by excluding samples extracted from the Molt-4 cell line (samples 15 and 16), 

















3.1.3 MtDNA/nDNA measurement variability 
The mean values and the inter-site coefficient of variation (%CV=mean*100%/standard 
deviation (SD) were calculated for each sample shipped (Table 1).  For this calculation, site #2 was 
omitted since their data was on a relative scale.  The average CV mean ± SD (range) for all samples 
was (raw data 94 ± 23 (50-142) %; log10 15.0 ± 4.8 (7.5-23.6) %).  This decreased to (raw d ta 44 ± 8 
(32-55) %, log10 10.7 ± 4.2 (4.1-18.1) %) if data from sites 4 and 5 were also omitted.  There was no 
relationship between the samples’ DNA concentration and their inter-site CV.  This remained true with 
or without sites 2, 4 and 5.   
 
3.2 Second shipment on dry ice 
Sets of 20 DNA samples on dry ice were sent from Vancouver to eight laboratories, all were 
confirmed to have arrived still frozen except the sipment to Australia that was cold.  Each site 
determined the mtDNA content of the samples, expressed as the mtDNA/nDNA ratio, and sent data 
back.  As before, site 2 data were on a relative scale rather than an absolute one.  While assaying 
samples from the second shipment, two sites noticed hat, for some samples, their mtDNA/nDNA 
measurements showed gene-dependent variability and accordingly, sent back results that they 
considered reliable for 11/20 and 13/20 samples, respectively.  
 
3.2.1 Concordance between duplicate samples 
Within the 20 samples, two were present in duplicate (#6 was a duplicate of #19 and #12 of 
#20) (Table 1), something that was not known by the participants.  Seven sites provided data for these 
samples.  The absolute % difference between the duplicates (∆ between duplicates*100%/mean of 
duplicates) was calculated for each pair and averaged.  Results (mean % difference ± SD (range) raw 
11.7 ± 7.4% (0.8-26.3%); log10 1.8 ± 1.3% (0.2-4.2%) indicated generally good concordance between 
duplicates as six out of seven sites showed less than 15% (raw data) difference between duplicates.   
 
3.2.2 MtDNA/nDNA concordance between sites 
As before, for all 20 samples, results from each site were correlated to those of the other 8 sites 
individually, using both raw and log10-transformed data (Table 5A).  This one on one comparison 
between the sites revealed that all sites showed goo c rrelation between them except one site (#4) that 















#2 (raw data R2=0.872, p<0.0001; log10 R
2=0.736, p=0.001) and weakly so with site #1 (raw data 
R2=0.414, p=0.018; log10 R
2=0.001, p=0.906).  This poor correlation appeared driven in large part by 
two samples derived from the CRL 2061 cell line.  
Among the 20 samples, eleven were derived from the same cell line (K562) that had been 
cultured in the presence of thymidine analogues to alter the mtDNA content.  The limited data sets 
provided by two laboratories both included values for all eleven K562 samples.  If only the K562 
samples were considered, the correlation between the 9 sites was generally more uniform (mean 
[range] R2 = raw data 0.69 [0.29-0.94]; log10 0.61 [0.19-0.88]), despite a tendency toward lower R
2 
values given the reduced sample size (N=11 instead of 20) (Table 5B).  Notably, when all samples 
compared were derived from the same cell line, site #4 showed much improved correlations with the 
other sites.   
 
3.2.3 MtDNA/nDNA measurement variability 
The mean of the coefficient of variability between sites for all 20 samples (mean CV ± SD 
[range]) was (raw data 79 ± 48 [37-212] %; log10 24 ± 10 [9-35] %)  (Table 1).  Concordance improved 
if data from site #2 (relative scale) were omitted (raw data 71 ± 50 [37-212] %; log10 11 ± 5 [8-28] %), 
and further improved if site #4 was also omitted (raw data 56 ± 20 [37-125] %; log10 10 ± 2 [8-13] %). 
Interestingly, four of the five samples with the hig est overall log10 data variability were extracted from 
the fibroblast rhabdomyosarcoma cell line CRL 2061.  If only samples from a single cell line (K562 
(N=11)) were considered for all sites, the mean CV was (raw data 71 ± 20 [55-126] %; log10 32 ± 2 
[29-35] %), and this decreased to (raw data 56 ± 22[39-115] %; log10 9 ± 1 [8-11] %) if the relative 

















The various assays used in this study were internally reliable.  However, more work is needed 
before absolute quantification of mtDNA is sufficiently reproducible across laboratories to allow direct 
comparison between them, or development of clinically meaningful normal range values for use in 
clinical diagnosis and monitoring.  Although mtDNA is a material of choice for forensic nucleic acid 
analyses and is known for its relative stability, travel at room temperature, though very affordable, did 
not favor mtDNA/nDNA measurement reproducibility.  The apparent increase in mtDNA/nDNA 
content observed was likely caused by partial degradation of the nDNA during transport.  This also 
implies that the standard sample that was distributed for future standardization between laboratories 
cannot be used for this purpose as it was part of the room temperature shipment.  Alternatively, it is
possible that partial degradation of the DNA linearized the mtDNA, rendering it more accessible to 
polymerases.  From this exercise, it would clearly be recommended that DNA samples be kept frozen 
until analyzed.  Because of this, the correlations between sites presented in Tables 4A and 4B should 
be interpreted with caution, as DNA degradation waslikely a factor.  Nevertheless, 6 of the 9 sites 
demonstrated good concordance between them. 
For the second shipment on dry ice, in agreement with observations from a previous smaller 
study (Hammond, Sayer et al. 2003), good correlation was observed between 8 of the 9 sites.  
However, significant variability between sites remained with respect to the absolute mtDNA/nDNA 
values.  This was illustrated by the inter-site CV which was above 200% for some samples derived 
from the CRL 2061 cell line, a high figure considerng that intra-site variability (CV) for 
mtDNA/nDNA assay is typically ≤15%. Log10-transforming the data reduced the inter-site variability, 
as could be expected.  A number of factors could inf ue ce the variability in mtDNA/nDNA values 
measured between sites.  These include but are not r stricted to the specificity of the assay primers and
the specificity of the detection method used (SYBR green vs. fluorescent probes), the copy number of 
the nuclear gene amplified, potential polymorphisms and DNA rearrangements, the target gene’s PCR 
efficiencies, and the methodology itself.  A total of nine different assays were used among the 
participating sites, and the two sites using the same primer sets did not show higher than average 
correlation between them.  This may be due to the fact that different detection systems were used. 
Each assay uses unique sets of primers targeting a mitochondrial gene and a nuclear DNA gene.  















amplify the DNA as even within laboratories, some genes can yield more variable results than others.  
Insufficient specificity on the part of the nDNA primers would evidently impact this assay.  Should any 
of the primers amplify unintentional targets such as pseudogenes or nuclear genes that are subject to 
chromosomal rearrangements, the value of the mtDNA/nDNA ratio would be affected.  Nuclear DNA 
primers should ideally be targeted toward single-copy nuclear genes having low incidence of inter-
individual polymorphisms and mutations.  If a high copy number gene is chosen, the exact number of 
copies should be considered if the mtDNA/nDNA ratio is to be compared to that generated using single 
copy nuclear genes.  Of course, the PCR efficiency of both the mtDNA and nDNA amplicons should 
be highly similar and the DNA concentration range yielding stable mtDNA/nDNA should be 
determined.  Nuclear DNA non-coding pseudogenes, although less common than mitochondrial 
pseudogenes (Zhang and Gerstein 2004), are especially prevalent for ribosomal RNA genes (Griffiths-
Jones 2007).  Indeed, based on Primer-BLASTing, some assays used in this study may have 
unintentionally amplified other products including uclear target pseudogenes with high or even 
complete homology.  These homologous DNA amplicons may be undetectable by the Tm curve often 
used to evaluate PCR primer’s specificity, yet they would significantly decrease mtDNA/nDNA ratio.  
 In addition, it is well recognized that chromosomal re rrangements, resulting in copy number 
variants, occur within the human genome. Although copy number variants have been associated with 
disease and malignancies (Conrad and Antonarakis 2007; Cooper, Nickerson et al. 2007), and are 
known to exist in several of the cell lines used in this study (Cottier, Tchirkov et al. 2004), they are 
also found in healthy individuals and are more common than initially expected (Scherer, Lee et al. 
2007; Perry, Yang et al. 2008).  As the cell lines used for this study are transformed and mostly derived 
from cancer patients, their DNA could bear important chromosomal rearrangements that may or may 
not affect amplification by primers targeting genes that vary from one assay to another.  This could be 
at least partially responsible for the higher inter-site variability observed with some samples.  Given 
that quantification can be nDNA gene-specific, consistent results with two independent nDNA genes 
can help rule out the possibility of unintended nuclear amplification. 
Mitochondrial DNA pseudogenes are very common through t the nuclear genome 
(Bensasson, Zhang et al. 2001; Yao, Kong et al. 2008) and pose many challenges to mtDNA research.  
As they can vary from one individual to another, from one cell line to another, some of the variability 
observed between the sites could be explained by mitochondrial pseudogenes.  Testing two mtDNA 















would confirm the absence of mitochondrial pseudogene amplification.  Using a single type of cultured 
cells when studying mtDNA quantification in would avoid many of the issues raised above. 
Sequencing of the human genome and tools such as BLAST and Primer-BLAST can greatly 
assist in the design of assay primers.  Of note, many primers used in this study were designed before 
the availability of these tools.  Future studies such as this one should consider reporting not only the 
mtDNA/nDNA ratio but rather each gene copy number separately.  This would allow the assessment of 
accuracy and concordance across sites and would give information on whether the source of 
discordance lies with the mitochondrial or the nuclear gene quantification. 
The fact that all sites showed high concordance for the K562-only derived samples reinforces 
the likelihood that single vs. multicopy genes, cell line-specific DNA alterations and/or polymorphisms 
may have affected the performance or applicability of some assays.  As several of the samples were 
extracted from cells exposed to drugs such as zidovu ine, stavudine or simvastatin, there is a remote 
possibility that the drugs may affect the primer binding sites, hence the assay.  From this data, it is 
difficult to ascertain how these factors may influenc  mtDNA measurements in human clinical samples 
from various genetic make-up and for the study of various diseases, however one can assume that 
clinical samples may harbor fewer chromosomal rearrangements than transformed cell lines.  These 
results suggest that mtDNA quantification assays need to be designed carefully and several specific 
recommendations can be made based on this study to increase reproducibility and accuracy of 
mtDNA/nDNA determinations, in addition to the usual qPCR assay design steps.  
 
5. Conclusions 
Our results showed good correlation between laboratories, indicating that within lab 
comparisons or comparison of relative mtDNA/nDNA betw en labs should be reliable.  However, 
absolute mtDNA/nDNA ratio values were highly variable across sites, something that is probably 
partially due to the fact that samples were derived mostly from transformed cultured cells. 
Furthermore, our results indicated that for such measurement as mtDNA/nDNA ratio, transportation of 
samples must take place under frozen conditions.  Although human clinical samples may have yielded 
less variable results, further efforts in standardization and evaluation of proficiency in reporting 
mtDNA content are clearly needed if the goal is to tandardize mtDNA content reporting and establish 
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Table 1.  Description of the two shipments: the cell lines from which the DNA samples were extracted an the variability (CV) of the 
mtDNA/nDNA ratio values provided for each sample by the N participating sites. 
Shipment # 1 (room temperature)   Raw data  Log -transformed data  
sam
ple  
Cell line  Cell Type  # sites  mtDNA/nDNA  Range  CV mtDNA/nDNA  Range  CV 
   (N) (mean ± SD)  (%) (mean ± SD)  (%) 
1 BKT-143 Osteosarcoma 8 337 ± 295 32-885 88 2.89 ± 0.23 2.69-3.39 8 
2 A.301 CD4 T cell line 8 387 ± 348 47-1201 90 2.67 ± 0.43 2.04-3.37 16 
3 CEM-1a Acute T lymphoblastic leukemia 8 418 ± 440 25-1310 105 2.69 ± 0.42 1.95-3.26 16 
4 CEM-2 Acute T lymphoblastic leukemia 8 628 ± 655 90-2091 104 2.61 ± 0.47 1.80-3.26 18 
5 CEM-3 Acute T lymphoblastic leukemia 8 644 ± 657 63-1835 102 2.64 ± 0.47 1.74-3.26 18 
6 CEM-4 Acute T lymphoblastic leukemia 8 667 ± 623 55-1814 94 2.63 ± 0.41 1.95-3.32 16 
7 HepG2 Hepatocellular carcinoma 8 711 ± 645 89-1806 91 3.07 ± 0.28 2.81-3.53 9 
8 HL60 Promyelocytic leukemia 8 719 ± 550 158-1906 76 2.70 ± 0.46 1.94-3.39 17 
9 HL60 Promyelocytic leukemia 8 740 ± 797 109-2328 108 2.67 ± 0.47 2.12-3.39 18 
10 HUT78 T cell lymphoma 8 797 ± 689 309-2418 86 2.80 ± 0.29 2.49-3.38 10 
11 HUT78 T cell lymphoma 8 801 ± 913 133-2447 114 2.75 ± 0.33 2.20-3.28 12 
12 K562 Erythromyeloblastoid leukemia  8 803 ± 842 87-2435 105 2.85 ± 0.37 2.26-3.41 13 
13 MCF7.2 Breast cancer 8 859 ± 478 396-1887 56 2.61 ± 0.62 1.64-3.58 24 
14 MCF7.2 Breast cancer 8 878 ± 436 305-1821 50 2.67 ± 0.53 1.91-3.56 20 
15 Molt-4 Acute T lymphoblastic leukemia 8 899 ± 658 494-2461 73 2.90 ± 0.22 2.48-3.26 8 
16 Molt-4 Acute T lymphoblastic leukemia 8 940 ± 1257 80-3634 134 2.88 ± 0.22 2.60-3.28 7 
17 PBMC Peripheral blood mononuclear cells 8 972 ± 1377 44-3796 142 2.40 ± 0.52 1.40-3.12 21 
18 PBMC Peripheral blood mononuclear cells 8 983 ± 892 180-2560 91 2.36 ± 0.45 1.50-2.95 19 
19 U937 Monocytic leukemia  8 1457 ± 1103 649-3421 76 2.45 ± 0.39 1.67-3.08 16 
Shipment # 2 (dry ice)   Raw data  Log -transformed data  
sam
ple  
Cell line  Cell Type   mtDNA/nDNA  Range  CV mtDNA/nDNA  Range  CV 
   (N) (mean ± SD)  (%) (mean ± SD)  (%) 
1 K562 b Erythromyeloblastoid leukemia  8 832 ± 322 240-1245 39 2.88 ± 0.23 2.38-3.10 7.9 
2 K562 Erythromyeloblastoid leukemia  8 1287 ± 830 359-3046 64 3.03 ± 0.28 2.56-3.48 9.2 
3 CRL 2061c Fibroblast rhabdomyosarcoma 7 51 ± 26 21-101 51 1.66 ± 0.22 1.33-2.00 13 
4 CRL 2061 Fibroblast rhabdomyosarcoma 8 268 ± 568 32-1671 212 1.96 ± 0.55 1.50-3.22 28 
5 K562 Erythromyeloblastoid leukemia  8 805 ± 383 253-1273 48 2.85 ± 0.24 2.40-3.10 8.5 
6 HEK 293 Embryonic Kidney 7 1659 ± 1280 315-3717 77 3.09 ± 0.39 2.50-3.57 13 
7 K562 Erythromyeloblastoid leukemia  8 786 ± 357 304-1431 45 2.85 ± 0.22 2.48-3.16 7.6 
8 K562 Erythromyeloblastoid leukemia  8 797 ± 318 237-1247 40 2.86 ± 0.23 2.38-3.10 7.9 
9 K562 Erythromyeloblastoid leukemia  8 680 ± 298 296-1161 44 2.79 ± 0.22 2.47-3.06 7.8 
10 K562 Erythromyeloblastoid leukemia  8 790 ± 453 240-1661 57 2.83 ± 0.27 2.38-3.22 9.4 















12 TF-1 Erythroleukemia 7 415 ± 196 151-658 47 2.56 ± 0.25 2.18-2.82 10 
13 K562 Erythromyeloblastoid leukemia  8 1167 ± 614 375-2210 53 3.01 ± 0.25 2.57-3.34 8.4 
14 K562 Erythromyeloblastoid leukemia  8 949 ± 649 275-2331 68 2.90 ± 0.27 2.44-3.37 9.4 
15 K562 Erythromyeloblastoid leukemia  8 669 ± 321 211-1085 48 2.77 ± 0.25 2.32-3.04 9.2 
16 Panc-1 Pancreatic carcinoma 7 1324 ± 590 340-1801 45 3.06 ± 0.28 2.53-3.26 9.1 
17 CRL 2061 Fibroblast rhabdomyosarcoma 8 354 ± 723 47-2140 204 2.13 ± 0.52 1.68-3.33 24 
18 K562 Erythromyeloblastoid leukemia  8 2873 ± 3293 720-10814 115 3.30 ± 0.36 2.86-4.03 11 
19d HEK 293 Embryonic Kidney 7 1639 ± 1209 320-3588 74 3.10 ± 0.37 2.51-3.55 12 
20e TF-1 Erythroleukemia 7 429 ± 199 151-621 46 2.58 ± 0.25 2.18-2.79 10 
 
a, CEM 1-4 were derived from the same cell line exposed to NRTIs for 7 days (Galluzzi, Pinti et al. 2005) ; b, the K562 samples were all derived 
from the same cell line exposed to various concentrations of zidovudine or stavudine for several weeks (Papp, Gadawski et al. 2008); c, the three 
CRL 2061 samples were derived from the same primary cell line differentiated into muscle cells and exposed to 0.1 µM simvastatin (personal 














Table 2.  Characteristics of the various assays used by participating sites.  The sites are listed in alphabetical order according to 











Nuclear gene Size  (bp) 














from 3’ end) 
18S rRNA  531 
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single mismatch position 
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RNA polymerase II 632  
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end) 
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Milan Cytochrome b 73 
Likely  
(mismatch at 3’ 
end) 
Chemokine (C-C motif) 
receptor 2 (CCR2) 66 
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mismatches position 5 or 
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Table 3. Effect of shipping back and forth at room te perature on mtDNA/nDNA quantification: correlations between mtDNA/nDNA 
values measured in Modena for sample sets shipped from each site back to Modena and values determined by the Modena site for their 
set of samples. 
Site  Modena 1 2 3 4 5 6 7 8 9 10 11 
             
Samples a (N) 19 18 18 19 19 18 19 17 18 18 17 19 
mtDNA/nDNA              






1731 93-743 53-395 76-699 68-644 
88-
2077 
      % change  N/A +40 +118 +0.6 +165 +244 +200 +68 -27 +26 +16 +118 
Pearson’s b             
      R2 1.0 0.93 0.90 0.62 0.85 0.62 0.82 0.78 0.83 0.68 0.84 0.72 
      Slope 1.0 1.07 1.45 0.42 1.71 1.56 1.66 0.83 0.36 0.55 0.72 1.69 
      p value  --- <0.0001 <0.0001 <0.0001 <0.0001 0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
a In some instances, the assay did not meet the assayquality control and no value was generated. 
b The correlations were between the measurements made by the Modena laboratory on the set of samples assigned to their site and 
















Table 4A. Pearson’s correlations for the mtDNA/nDNA values obtained by each sites for the first shipment at room temperature for all 
samples (N=19).  Correlations of raw data are shown against clear background while those of log10-transformed data are shown against 
a grey background. Bold indicates no significant correlation. 
 
First shipment at room temperature, Pearson’s corre lation  











































































































































































Table 4B. Pearson’s correlations for the  mtDNA/nDNA values obtained by each sites for the first shipment at room temperature for 
all samples except samples 15 and 16 (N=17).  Correlations of raw data are shown against clear background while those of log10-
transformed data are shown against a grey background.  Bold indicates no significant correlation. 
 
First shipment at room temperature, Pearson’s correlation (minus samples 1 5 and 16)  












































































































































































Table 5A. Pearson’s correlations for the mtDNA/nDNA values obtained by each sites for the second shipment on dry ice (N=20*).  
Correlations of raw data are shown against clear background while those of log10-transformed data are shown against a grey 
background.  Bold indicates no significant correlation. 
Second shipment on dry ice, Pearson’s correlation  













































































































































































Table 5B. Pearson’s correlation (R2) and p values between mtDNA/nDNA values obtained by individual sites for the second shipment 
on dry ice, considering only the samples derived from the K562 cell line (N=11).  Correlations of raw data are shown against clear 
background while those of log10-transformed data are shown against a grey background.  Bold indicates no significant correlation. 
 
Second shipment on dry ice,  K562 DNA only, Pearson’s correlation  
Site  1 2 3 4 5 6 7 8 9 
1 - R
2=0.646 
p=0.003 
R2=0.796 
p=0.0002 
R2=0.567 
p=0.008 
R2=0.423 
p=0.030 
R2=0.613 
p=0.004 
R2=0.487 
p=0.017 
R2=0.469 
p=0.020 
R2=0.693 
p=0.001 
2 R
2=0.787 
p=0.0003 - 
R2=0.780 
p=0.0003 
R2=0.736 
p=0.001 
R2=0.299 
p=0.082 
R2=0.747 
p=0.001 
R2=0.326 
p=0.067 
R2=0.562 
p=0.008 
R2=0.855 
p<0.0001 
3 R
2=0.901 
p<0.0001 
R2=0.873 
p<0.0001 
- 
R2=0.726 
p=0.001 
R2=0.561 
p=0.008 
R2=0.799 
p=0.0002 
R2=0.488 
p=0.017 
R2=0.677 
p=0.002 
R2=0.880 
p<0.0001 
4 R
2=0.706 
p=0.001 
R2=0.872 
p<0.0001 
R2=0.854 
p<0.0001 
- 
R2=0.249 
p=0.119 
R2=0.479 
p=0.018 
R2=0.185 
p=0.187 
R2=0.450 
p=0.024 
R2=0.656 
p=0.002 
5 R
2=0.597 
p=0.005 
R2=0.478 
p=0.019 
R2=0.664 
p=0.002 
R2=0.451 
p=0.024 - 
R2=0.431 
p=0.028 
R2=0.368 
p=0.048 
R2=0.431 
p=0.028 
R2=0.567 
p=0.007 
6 R
2=0.901 
p<0.0001 
R2=0.835 
p<0.0001 
R2=0.879 
p<0.0001 
R2=0.669 
p=0.002 
R2=0.541 
p=0.010 
- 
R2=0.413 
p=0.033 
R2=0.644 
p=0.003 
R2=0.867 
p<0.0001 
7 R
2=0.431 
p=0.028 
R2=0.362 
p=0.050 
R2=0.482 
p=0.018 
R2=0.288 
p=0.089 
R2=0.413 
P=0.033 
R2=0.451 
p=0.024 
- 
R2=0.407 
p=0.035 
R2=0.314 
p=0.073 
8 R
2=0.738 
p=0.001 
R2=0.709 
p=0.001 
R2=0.822 
p=0.0001 
R2=0.641 
p=0.003 
R2=0.539 
p=0.010 
R2=0.771 
p=0.0004 
R2=0.494 
p=0.016 - 
R2=0.662 
p=0.002 
9 R
2=0.910 
p<0.0001 
R2=0.917 
p<0.0001 
R2=0.941 
p<0.0001 
R2=0.805 
p=0.0002 
R2=0.646 
p=0.003 
R2=0.934 
p<0.0001 
R2=0.379 
p=0.044 
R2=0.795 
p=0.0002 
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